RBC Capital Markets Initiates Coverage on Biohaven Pharmaceutical, Assigning an Outperform Rating
On Friday, RBC Capital Markets started coverage on Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and gave it an Outperform rating with a price target of $62.00. RBC Capital Markets praised Biohaven for its strategic approach in identifying and developing promising technologies within the pharmaceutical industry.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
